Market Overview

UPDATE: JP Morgan Initiates DaVita HealthCare Partners at Overweight on Growth Outlook

Share:
Related DVA
Stephen Mandel's Lone Pine Capital Loves Tech, Consumer Stocks
Worst Performing Industries For February 13, 2015
DaVita Healthcare Partners CFO exits to return to biopharma (Seeking Alpha)

JP Morgan initiated coverage on DaVita HealthCare Partners (NYSE: DVA) with an Overweight rating and a $125 price target.

JP Morgan said, "By combining the steady growth and cash generation of the company's core dialysis business with the best physician practice management asset in the country, HealthCare Partners (HCP), CEO Kent Thiry has positioned DVA at the forefront of a potentially long-term shift in healthcare delivery and reimbursement heading into reform implementation. The capability of properly incentivized, sophisticated primary care physicians to lower system costs is unquestioned, leaving only the pace and magnitude of opportunity to be decided going forward, with DVA perhaps best positioned of all to benefit."

DaVita HealthCare Partners closed at $110.87 on Wednesday.

Latest Ratings for DVA

DateFirmActionFromTo
Mar 2015Deutsche BankMaintainsHold
Nov 2014JP MorganMaintainsOverweight
Sep 2014KeyBancDowngradesBuyHold

View More Analyst Ratings for DVA
View the Latest Analyst Ratings

Posted-In: JP MorganAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (DVA)

Around the Web, We're Loving...